Show simple item record

dc.contributor.authorMetcalf, C J E
dc.contributor.authorKlepac, P
dc.contributor.authorFerrari, M
dc.contributor.authorGrais, RF F
dc.contributor.authorDjibo, A
dc.contributor.authorGrenfell, B T
dc.date.accessioned2011-05-23T20:55:41Z
dc.date.available2011-05-23T20:55:41Z
dc.date.issued2011-02
dc.identifier.citationModelling the first dose of measles vaccination: the role of maternal immunity, demographic factors, and delivery systems. 2011, 139 (2):265-74 Epidemiol. Infect.en
dc.identifier.issn1469-4409
dc.identifier.pmid20525415
dc.identifier.doi10.1017/S0950268810001329
dc.identifier.urihttp://hdl.handle.net/10144/129954
dc.description.abstractMeasles vaccine efficacy is higher at 12 months than 9 months because of maternal immunity, but delaying vaccination exposes the children most vulnerable to measles mortality to infection. We explored how this trade-off changes as a function of regionally varying epidemiological drivers, e.g. demography, transmission seasonality, and vaccination coverage. High birth rates and low coverage both favour early vaccination, and initiating vaccination at 9-11 months, then switching to 12-14 months can reduce case numbers. Overall however, increasing the age-window of vaccination decreases case numbers relative to vaccinating within a narrow age-window (e.g. 9-11 months). The width of the age-window that minimizes mortality varies as a function of birth rate, vaccination coverage and patterns of access to care. Our results suggest that locally age-targeted strategies, at both national and sub-national scales, tuned to local variation in birth rate, seasonality, and access to care may substantially decrease case numbers and fatalities for routine vaccination.
dc.language.isoenen
dc.publisherCambridge University Pressen
dc.relation.urlhttp://journalseek.net/en
dc.rightsArchived with thanks to Epidemiology and Infection and Cambridge University Pressen
dc.subject.meshAgingen
dc.subject.meshDelivery of Health Careen
dc.subject.meshFemaleen
dc.subject.meshHumansen
dc.subject.meshImmunity, Maternally-Acquireden
dc.subject.meshImmunization Scheduleen
dc.subject.meshInfanten
dc.subject.meshMeaslesen
dc.subject.meshMeasles Vaccineen
dc.subject.meshModels, Theoreticalen
dc.subject.meshPregnancyen
dc.subject.meshSeasonsen
dc.subject.meshVaccinationen
dc.titleModelling the first dose of measles vaccination: the role of maternal immunity, demographic factors, and delivery systems.en
dc.typeArticleen
dc.contributor.departmentDepartment of Ecology and Evolutionary Biology, Princeton University, NJ 0854, USA. cmetcalf@princeton.eduen
dc.identifier.journalEpidemiology and Infectionen
refterms.dateFOA2019-03-04T08:45:16Z
html.description.abstractMeasles vaccine efficacy is higher at 12 months than 9 months because of maternal immunity, but delaying vaccination exposes the children most vulnerable to measles mortality to infection. We explored how this trade-off changes as a function of regionally varying epidemiological drivers, e.g. demography, transmission seasonality, and vaccination coverage. High birth rates and low coverage both favour early vaccination, and initiating vaccination at 9-11 months, then switching to 12-14 months can reduce case numbers. Overall however, increasing the age-window of vaccination decreases case numbers relative to vaccinating within a narrow age-window (e.g. 9-11 months). The width of the age-window that minimizes mortality varies as a function of birth rate, vaccination coverage and patterns of access to care. Our results suggest that locally age-targeted strategies, at both national and sub-national scales, tuned to local variation in birth rate, seasonality, and access to care may substantially decrease case numbers and fatalities for routine vaccination.


Files in this item

Thumbnail
Name:
468_Modelling the first dose of ...
Size:
472.9Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record